SBIR-STTR Award

Development and evaluation of diffuse correlation spectroscopy to monitor cerebral blood flow and detect intraventricular hemorrhage in extremely premature infants
Award last edited on: 2/16/2024

Sponsored Program
STTR
Awarding Agency
NIH : NINDS
Total Award Amount
$773,802
Award Phase
2
Solicitation Topic Code
853
Principal Investigator
Bernhard Zimmermann

Company Information

149 Medical Inc

1173 Main Street
Bolton, MA 01740
   N/A
   N/A
   www.149medical.com

Research Institution

Brigham and Womens Hospital

Phase I

Contract Number: 1R42NS110337-01A1
Start Date: 9/30/2019    Completed: 3/31/2021
Phase I year
2019
Phase I Amount
$149,969
Every year in the United States about 30% of the 60,000 infants born extremely premature (<30 weeks gestational age and <1000 g birth-weight [ELGA]) develop intraventricular hemorrhage (IVH). IVH is associated with high risk for cerebral palsy and significant intellectual disability, causing lifelong implications for affected children and their families and considerable economic burden. IVH is caused by the rupture of the fragile capillaries in the germinal matrix which cannot withstand fluctuations in cerebral blood flow (CBF). In >90% of cases, these injuries occur during the first three postnatal days during a period of cardiorespiratory instability that has a direct effect on CBF, which results in periods of cerebral hypo- and hyper-perfusion. Current management strategies, such as changes in ventilation or inotrope support, are blind to the impact on CBF. Improved bedside technologies to continuously monitor CBF are urgently needed to allow the clinician to make informed decisions, to optimize current strategies and foster the development of new interventions to reduce the incidence of IVH in ELGA infants and to improve developmental outcomes. Building on 149 Medical founding team's ten years of success measuring infants with non-invasive bedside optical methods, we propose to design and build a novel fast multi-distance diffuse correlation spectroscopy (DCS) system, optimized for continuous monitoring of CBFi in ELGA infants. DCS directly quantifies an index of cerebral blood flow (CBFi) by measuring the temporal fluctuations of light generated by the dynamic scattering of moving red blood cells. To be of use in the ELGA infant, this bedside monitor needs to be safe, continuous, precise, reliable, quantitative and gently wearable. These pre-requisites will be met by designing an optical sensor which can be gently applied to the ELGA infant. The novel DCS system will be initially tested by the 149 Medical's team in phantoms to verify performance and demonstrate precision and accuracy of flow estimates. The system will then be tested in more mature, stable premature infants at the Brigham and Women's Hospital (BWH) NICU to evaluate feasibility of long measurements, compatibility with the NICU environment, skin integrity after long monitoring periods, and in-vivo algorithm validation. Finally, the device will be used in 50 ELGA infants during the first 72 hours of life to test our hypothesis that DCS-measured CBFi fluctuations and pressure-passive events correlate with incidence and severity of IVH. Our goal is to provide a much-needed cerebral blood flow monitor to guide individualized treatment with the goal of reducing the risk of IVH and improving long term neurodevelopmental outcomes among ELGA infants. This study in 50 ELGA infants will set the stage for a larger trial alongside commercialization.

Public Health Relevance Statement:
PROJECT NARRATIVE There is a great need for a bedside, non-invasive and continuous neuromonitoring tool to provide a robust measure of cerebral blood flow in premature infants. We propose to develop a novel near-infrared diffuse correlation spectroscopy (DCS) system optimized for monitoring of the cerebral blood flow index in extremely premature infants. The successful development, validation and demonstration of clinical feasibility and effectiveness of our proposed technology will lead to new patient management approaches for reducing neurological injury, protecting neurocognitive function, and reducing the overall morbidity and mortality associated with prematurity.

Project Terms:
Affect; Elderly; senior citizen; older person; older adult; later life; late life; geriatric; elders; advanced age; Algorithms; Automobile Driving; driving; Birth Weight; Birth; Parturition; Blood Pressure; Blood Vessels; vascular; Boston; Blood capillaries; capillary; Cardiovascular system; circulatory system; Heart Vascular; Cardiovascular Organ System; Cardiovascular Body System; Cardiovascular; Cerebral Palsy; cerebrovascular blood flow; cerebrocirculation; cerebral circulation; cerebral blood flow; brain blood flow; Cerebrovascular Circulation; youngster; childrens'; children; Children (0-21); Child Youth; 0-11 years old; Child; Electrocardiography; EKG; ECG; Electrocardiogram; Environment; blood corpuscles; Red Cell; Red Blood Cells; Marrow erythrocyte; Erythrocytic; Blood erythrocyte; Erythrocytes; Family; Fetal Age; Chronologic Fetal Maturity; Gestational Age; Goals; Head; Hospitals; Incidence; indexing; Infant; preterm neonate; preterm infant human; preterm infant; preterm baby; premature infant human; premature baby; infants born prematurely; infants born premature; Premature Infant; heavy metal lead; heavy metal Pb; Pb element; Lead; Photoradiation; Light; Morbidity; Morbidity - disease rate; mortality; Mothers; Multiple Births; Multiple Birth Offspring; optical; Optics; Patients; Perfusion; Physicians; pilot study; Pilot Projects; pressure; Pulse Oximetry; Reperfusion Damage; Ischemia-Reperfusion Injury; Reperfusion Injury; Risk; natural Rubber; Latex Rubber; Rubber; biological signal transduction; Signaling; Signal Transduction Systems; Intracellular Communication and Signaling; Cell Signaling; Cell Communication and Signaling; Signal Transduction; Spectrum Analyses; Spectroscopy; Spectrum Analysis; Survival Rate; Target Populations; Technology; Testing; Time; United States; Ventilation; Environmental air flow; Woman; Work; Measures; Healthcare Costs; Health Costs; Health Care Costs; Injury; base; dosage; sensor; improved; Mechanical ventilation; mechanical respiratory assist; Clinical; Diffuse; premature; prematurity; Phase; Variant; Variation; Medical; Evaluation; Cerebral hemisphere; Brain Hemisphere; disability; Bilateral; intraventricular hemorrhage; Cerebrum; cerebral; Fostering; Measurement; Brain Injuries; brain-injured; brain damage; Acquired brain injury; Bedside Technology; Bedside Computings; light weight; lightweight; tool; Life; Hour; Severities; Event; postnatal; Pattern; System; Intellectual functioning disability; intellectual and developmental disability; Intellectual limitation; Intellectual disability; Neurocognitive; Outcome Study; Performance; success; Hydrogels; novel; Devices; Positioning Attribute; Position; Nervous System Trauma; neurotrauma; Neurological trauma; Neurological Injury; Neurological Damage; Nervous System damage; Nervous System Injuries; Intervention; interventional strategy; Intervention Strategies; Skin; Effectiveness; Length; Economic Burden; in vivo; Optical Methods; Update; Validation; Monitor; trend; Development; developmental; Image; imaging; design; designing; Neurodevelopmental Disability; Rupture; Outcome; Neonatal; blind; Population; optical sensor; non-invasive monitor; noninvasive monitor; optical fiber; commercialization; high risk; standard of care; flexibility; flexible; Executive Dysfunction; Executive Impairment; Executive Function Deficit; individualized medicine; unique treatment; tailored treatment; tailored therapy; tailored medical treatment; individualized treatment; individualized therapy; individualized patient treatment; customized treatment; customized therapy; personalized medicine; personalized treatment; personalized therapy; personalization of treatment; opioid epidemic; opioid crisis; opiate crisis

Phase II

Contract Number: 4R42NS110337-02
Start Date: 6/1/2021    Completed: 5/31/2023
Phase II year
2021
(last award dollars: 2022)
Phase II Amount
$623,833

Every year in the United States about 30% of the 60,000 infants born extremely premature (<30 weeks gestational age and <1000 g birth-weight [ELGA]) develop intraventricular hemorrhage (IVH). IVH is associated with high risk for cerebral palsy and significant intellectual disability, causing lifelong implications for affected children and their families and considerable economic burden. IVH is caused by the rupture of the fragile capillaries in the germinal matrix which cannot withstand fluctuations in cerebral blood flow (CBF). In >90% of cases, these injuries occur during the first three postnatal days during a period of cardiorespiratory instability that has a direct effect on CBF, which results in periods of cerebral hypo- and hyper-perfusion. Current management strategies, such as changes in ventilation or inotrope support, are blind to the impact on CBF. Improved bedside technologies to continuously monitor CBF are urgently needed to allow the clinician to make informed decisions, to optimize current strategies and foster the development of new interventions to reduce the incidence of IVH in ELGA infants and to improve developmental outcomes. Building on 149 Medical founding team's ten years of success measuring infants with non-invasive bedside optical methods, we propose to design and build a novel fast multi-distance diffuse correlation spectroscopy (DCS) system, optimized for continuous monitoring of CBFi in ELGA infants. DCS directly quantifies an index of cerebral blood flow (CBFi) by measuring the temporal fluctuations of light generated by the dynamic scattering of moving red blood cells. To be of use in the ELGA infant, this bedside monitor needs to be safe, continuous, precise, reliable, quantitative and gently wearable. These pre-requisites will be met by designing an optical sensor which can be gently applied to the ELGA infant. The novel DCS system will be initially tested by the 149 Medical's team in phantoms to verify performance and demonstrate precision and accuracy of flow estimates. The system will then be tested in more mature, stable premature infants at the Brigham and Women's Hospital (BWH) NICU to evaluate feasibility of long measurements, compatibility with the NICU environment, skin integrity after long monitoring periods, and in-vivo algorithm validation. Finally, the device will be used in 50 ELGA infants during the first 72 hours of life to test our hypothesis that DCS-measured CBFi fluctuations and pressure-passive events correlate with incidence and severity of IVH. Our goal is to provide a much-needed cerebral blood flow monitor to guide individualized treatment with the goal of reducing the risk of IVH and improving long term neurodevelopmental outcomes among ELGA infants. This study in 50 ELGA infants will set the stage for a larger trial alongside commercialization.

Public Health Relevance Statement:
PROJECT NARRATIVE There is a great need for a bedside, non-invasive and continuous neuromonitoring tool to provide a robust measure of cerebral blood flow in premature infants. We propose to develop a novel near-infrared diffuse correlation spectroscopy (DCS) system optimized for monitoring of the cerebral blood flow index in extremely premature infants. The successful development, validation and demonstration of clinical feasibility and effectiveness of our proposed technology will lead to new patient management approaches for reducing neurological injury, protecting neurocognitive function, and reducing the overall morbidity and mortality associated with prematurity.

Project Terms: